43/120
1.8 / 5 stars
All 120 Win/Lose results shown below
ARDX Roast Me summary
ARDELYX, INC. (ARDX). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 24 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseARDX / S&P -14.86% / 15.20% |
WinARDX / S&P 16.77% / 15.00% |
LoseARDX / S&P ARDX unavailable / 50.40% |
| 2026-Q12/3 |
WinARDX / S&P 2.74% / -4.33% |
WinARDX / S&P 18.24% / 11.30% |
LoseARDX / S&P ARDX unavailable / 27.70% |
| 2025-Q42/3 |
WinARDX / S&P 5.81% / 2.65% |
WinARDX / S&P 22.09% / 9.00% |
LoseARDX / S&P ARDX unavailable / 13.40% |
| 2025-Q32/3 |
WinARDX / S&P 40.56% / 8.12% |
WinARDX / S&P 58.12% / 4.61% |
LoseARDX / S&P ARDX unavailable / 13.45% |
| 2025-Q21/3 |
LoseARDX / S&P -20.16% / 10.94% |
WinARDX / S&P 83.88% / 4.83% |
LoseARDX / S&P ARDX unavailable / 10.63% |
| 2025-Q12/3 |
WinARDX / S&P -3.16% / -4.27% |
WinARDX / S&P 127.33% / 4.98% |
LoseARDX / S&P ARDX unavailable / 10.57% |
| 2024-Q41/3 |
LoseARDX / S&P -26.42% / 2.41% |
WinARDX / S&P 168.06% / 5.25% |
LoseARDX / S&P ARDX unavailable / 6.15% |
| 2024-Q31/3 |
LoseARDX / S&P -7.02% / 5.89% |
WinARDX / S&P 87.57% / 5.89% |
LoseARDX / S&P ARDX unavailable / 6.11% |
| 2024-Q21/3 |
LoseARDX / S&P 1.51% / 4.28% |
WinARDX / S&P 153.42% / 5.38% |
LoseARDX / S&P ARDX unavailable / 5.12% |
| 2024-Q12/3 |
WinARDX / S&P 17.74% / 10.56% |
WinARDX / S&P 152.32% / 5.71% |
LoseARDX / S&P ARDX unavailable / 5.59% |
| 2023-Q42/3 |
WinARDX / S&P 51.96% / 11.69% |
WinARDX / S&P 138.61% / 6.81% |
LoseARDX / S&P ARDX unavailable / 7.78% |
| 2023-Q32/3 |
WinARDX / S&P 20.35% / -3.27% |
WinARDX / S&P 1390.41% / 7.52% |
LoseARDX / S&P ARDX unavailable / -5.03% |
| 2023-Q21/3 |
LoseARDX / S&P -29.23% / 8.74% |
WinARDX / S&P 1494.80% / 9.50% |
LoseARDX / S&P ARDX unavailable / -8.57% |
| 2023-Q12/3 |
WinARDX / S&P 68.07% / 7.50% |
WinARDX / S&P 1483.20% / 10.77% |
LoseARDX / S&P ARDX unavailable / -15.69% |
| 2022-Q42/3 |
WinARDX / S&P 139.50% / 7.56% |
WinARDX / S&P 416.57% / 11.88% |
LoseARDX / S&P ARDX unavailable / -17.99% |
| 2022-Q31/3 |
WinARDX / S&P 101.69% / -4.88% |
LoseARDX / S&P -17.17% / 13.47% |
LoseARDX / S&P ARDX unavailable / -1.41% |
| 2022-Q20/3 |
LoseARDX / S&P -44.86% / -16.10% |
LoseARDX / S&P -58.15% / 13.71% |
LoseARDX / S&P ARDX unavailable / 11.04% |
| 2022-Q11/3 |
WinARDX / S&P -2.73% / -4.60% |
LoseARDX / S&P -69.22% / 15.97% |
LoseARDX / S&P ARDX unavailable / 42.23% |
| 2021-Q41/3 |
LoseARDX / S&P -16.67% / 11.03% |
WinARDX / S&P 33.36% / 15.00% |
LoseARDX / S&P ARDX unavailable / 96.40% |
| 2021-Q31/3 |
LoseARDX / S&P -82.59% / 0.58% |
WinARDX / S&P 35.76% / 10.77% |
LoseARDX / S&P ARDX unavailable / 69.42% |
| 2021-Q22/3 |
WinARDX / S&P 14.50% / 8.55% |
WinARDX / S&P 49.39% / 6.58% |
LoseARDX / S&P ARDX unavailable / 51.81% |
| 2021-Q11/3 |
LoseARDX / S&P 2.32% / 6.17% |
WinARDX / S&P 99.26% / -1.06% |
LoseARDX / S&P ARDX unavailable / 7.39% |
| 2020-Q42/3 |
WinARDX / S&P 23.24% / 12.15% |
WinARDX / S&P 43.36% / -3.72% |
LoseARDX / S&P ARDX unavailable / -33.42% |
| 2020-Q30/3 |
LoseARDX / S&P -24.13% / 8.93% |
LoseARDX / S&P ARDX unavailable / -2.04% |
LoseARDX / S&P ARDX unavailable / -27.10% |
| 2020-Q21/3 |
WinARDX / S&P 21.72% / 20.54% |
LoseARDX / S&P ARDX unavailable / -0.46% |
LoseARDX / S&P ARDX unavailable / -27.11% |
| 2020-Q10/3 |
LoseARDX / S&P -24.25% / -19.60% |
LoseARDX / S&P ARDX unavailable / 3.47% |
LoseARDX / S&P ARDX unavailable / -14.75% |
| 2019-Q42/3 |
WinARDX / S&P 59.68% / 9.07% |
WinARDX / S&P 102.57% / 5.36% |
LoseARDX / S&P ARDX unavailable / 2.99% |
| 2019-Q31/3 |
WinARDX / S&P 74.72% / 1.70% |
LoseARDX / S&P ARDX unavailable / 5.02% |
LoseARDX / S&P ARDX unavailable / 0.21% |
| 2019-Q20/3 |
LoseARDX / S&P -3.93% / 4.30% |
LoseARDX / S&P ARDX unavailable / 6.64% |
LoseARDX / S&P ARDX unavailable / 8.65% |
| 2019-Q11/3 |
WinARDX / S&P 56.42% / 13.65% |
LoseARDX / S&P ARDX unavailable / 8.12% |
LoseARDX / S&P ARDX unavailable / 14.29% |
| 2018-Q40/3 |
LoseARDX / S&P -58.85% / -13.52% |
LoseARDX / S&P -93.79% / 9.05% |
LoseARDX / S&P ARDX unavailable / 18.23% |
| 2018-Q31/3 |
WinARDX / S&P 17.57% / 7.71% |
LoseARDX / S&P ARDX unavailable / 10.21% |
LoseARDX / S&P ARDX unavailable / 19.06% |
| 2018-Q20/3 |
LoseARDX / S&P -26.73% / 3.43% |
LoseARDX / S&P ARDX unavailable / 9.03% |
LoseARDX / S&P ARDX unavailable / 14.46% |
| 2018-Q10/3 |
LoseARDX / S&P -23.48% / -0.76% |
LoseARDX / S&P ARDX unavailable / 7.68% |
LoseARDX / S&P ARDX unavailable / 12.46% |
| 2017-Q41/3 |
WinARDX / S&P 17.86% / 6.64% |
LoseARDX / S&P ARDX unavailable / 7.03% |
LoseARDX / S&P ARDX unavailable / 13.82% |
| 2017-Q31/3 |
WinARDX / S&P 9.80% / 4.48% |
LoseARDX / S&P ARDX unavailable / 5.68% |
LoseARDX / S&P ARDX unavailable / 17.57% |
| 2017-Q20/3 |
LoseARDX / S&P -59.68% / 3.09% |
LoseARDX / S&P ARDX unavailable / 4.83% |
LoseARDX / S&P ARDX unavailable / 17.74% |
| 2017-Q10/3 |
LoseARDX / S&P -10.92% / 6.07% |
LoseARDX / S&P ARDX unavailable / 3.67% |
LoseARDX / S&P ARDX unavailable / 13.32% |
| 2016-Q41/3 |
WinARDX / S&P 9.74% / 3.82% |
LoseARDX / S&P ARDX unavailable / 2.09% |
LoseARDX / S&P ARDX unavailable / 7.05% |
| 2016-Q31/3 |
WinARDX / S&P 48.22% / 3.85% |
LoseARDX / S&P ARDX unavailable / 0.20% |
LoseARDX / S&P ARDX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | ARDX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -39.94% | 20.78% |
| Annualized return | -39.94% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | ARDX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 163.45% | 83.14% |
| Annualized return | 21.38% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | ARDX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -62.98% | 319.30% |
| Annualized return | -9.46% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-24.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |